U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07432516) titled 'Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial' on Nov. 14, 2025.
Brief Summary: " Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) require optimized medical therapy to prevent recurrent cardiovascular events. This includes both antiplatelet and lipid-lowering strategies.
For antiplatelet therapy, dual antiplatelet therapy (DAPT) comprising aspirin and a potent P2Y12 inhibitor (such as ticagrelor) for 12 months is the current standard of care. While this regimen is effective in reducing ischemic events, it significantly increases the ...